Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12666554 | 0.90 | SMN1; SMN2 (0.60) | SMN1; SMN2HSD11B1HTT | |
| SCHEMBL24528929 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2CHRM1HSD11B1KMT2APOLB | |
| SCHEMBL2086743 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2CHRM1HSD11B1KMT2APOLB | |
| SCHEMBL23251671 | 0.81 | CHRM1 (0.40) | SMN1; SMN2CHRM1POLBKDM4ELMNA | |
| Hydrochloric Acid SCHEMBL23453806 | 0.80 | SMN1; SMN2 (0.54) | SMN1; SMN2CHRM1HSD11B1KMT2APOLB | |
| SCHEMBL23251540 | 0.80 | CHRM1 (0.38) | CHRM1KMT2APOLBKDM4EMEN1 | |
| SCHEMBL23251589 | 0.77 | HRH3 (0.41) | CHRM1KMT2APOLBLMNA | |
| SCHEMBL23251841 | 0.77 | SMN1; SMN2 (0.50) | SMN1; SMN2CHRM1HSD11B1KMT2APOLB | |
| SCHEMBL11919050 | 0.76 | SMN1; SMN2 (0.53) | SMN1; SMN2CHRM1POLBHTT | |
| SCHEMBL25561912 | 0.76 | SMN1; SMN2 (0.61) | SMN1; SMN2HSD11B1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-11685749-B2 | C26-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685749-B2 | C26-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | SMN1; SMN2 1321/4885CHRM1 4878/4885HSD11B1 3683/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | SMN1; SMN2 1139/4885CHRM1 4885/4885HSD11B1 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.